Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UNIPROT:P06889 (
Mol
)
630,302
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Severe acute respiratory syndrome
(
SARS
) coronavirus (CoV) contains a spike (S) protein that binds to a receptor molecule (angiotensin-converting enzyme 2; ACE2), induces membrane fusion, and serves as a neutralizing epitope. To study the functions of the S protein, we describe here the generation of
SARS
-CoV S protein-bearing vesicular stomatitis virus (VSV) pseudotype using a VSVdeltaG*/GFP system in which the G gene is replaced by the green fluorescent protein (GFP) gene (VSV-
SARS
-CoV-St19/GFP). Partial deletion of the cytoplasmic domain of
SARS
-CoV S protein (
SARS
-CoV-St19) allowed efficient incorporation into the VSV particle that enabled the generation of a high titer of pseudotype virus. Neutralization assay with anti-
SARS
-CoV antibody revealed that VSV-
SARS
-St19/GFP pseudotype infection is mediated by
SARS
-CoV S protein. The VSVdeltaaG*/SEAP system, which secretes alkaline phosphatase instead of GFP, was also generated as a VSV pseudotype having
SARS
-CoV S protein (VSV-
SARS
-CoV-St19/SEAP). This system enabled high-throughput analysis of
SARS
-CoV S protein-mediated cell entry by measuring alkaline phosphatase activity. Thus, VSV pseudotyped with
SARS
-CoV S protein is useful for developing a rapid detection system for neutralizing antibody specific for
SARS-CoV infection
as well as studying the S-mediated cell entry of
SARS
-CoV.
Methods
Mol
Biol 2008
PMID:Pseudotyped vesicular stomatitis virus for analysis of virus entry mediated by SARS coronavirus spike proteins. 1905 67
The construction of coronavirus (CoV) infectious clones had been hampered by the large size of the viral genome (around 30kb) and the instability of plasmids carrying CoV replicase sequences in Escherichia coli. Several approaches have been developed to overcome these problems. Here we describe the engineering of CoV full-length cDNA clones using bacterial artificial chromosomes (BACs). In this system the viral RNA is expressed in the cell nucleus under the control of the cytomegalovirus promoter and further amplified in the cytoplasm by the viral replicase. The BAC-based strategy is an efficient system that allows easy manipulation of CoV genomes to study fundamental viral processes and also to develop genetically defined vaccines. The procedure is illustrated by the cloning of the genome of
SARS
coronavirus, Urbani strain.
Methods
Mol
Biol 2008
PMID:Engineering infectious cDNAs of coronavirus as bacterial artificial chromosomes. 1905 70
The zoonotic transmission of
SARS
coronavirus from animals to humans revealed the potential impact of coronaviruses on mankind. This incident also triggered several surveillance programs to hunt for novel coronaviruses in human and wildlife populations. Using classical RT-PCR assays that target a highly conserved sequence among coronaviruses, we identified the first coronaviruses in bats. These assays and the cloning and sequencing of the PCR products are described in this chapter. Using the same approach in our subsequent studies, we further detected several novel coronaviruses in bats. These findings highlighted the fact that bats are important reservoirs for coronaviruses.
Methods
Mol
Biol 2008
PMID:Detection of group 1 coronaviruses in bats using universal coronavirus reverse transcription polymerase chain reactions. 1905 71
Coronavirus reverse genetic systems have become valuable tools for studying the molecular biology of coronavirus infections. They have been applied to the generation of recombinant coronaviruses, selectable replicon RNAs, and coronavirus-based vectors for heterologous gene expression. Here we provide a collection of protocols for the generation, cloning, and modification of full-length coronavirus cDNA using vaccinia virus as a cloning vector. Based on cloned coronaviral cDNA, we describe the generation of recombinant coronaviruses and stable cell lines containing coronaviral replicon RNAs. Initially, the vaccinia virus-based reverse genetic system was established for the generation of recombinant human coronavirus 229E. However, it is also applicable to the generation of other coronaviruses, such as the avian infectious bronchitis virus, mouse hepatitis virus, and
SARS
coronavirus.
Methods
Mol
Biol 2008
PMID:Generation of recombinant coronaviruses using vaccinia virus as the cloning vector and stable cell lines containing coronaviral replicon RNAs. 1905 73
Immunological detection of viruses and their components by monoclonal antibodies is a powerful method for studying the structure and function of viral molecules. Here we describe detailed methods for establishing monoclonal antibodies against
severe acute respiratory syndrome
coronavirus (SARS-CoV). B cell hybridomas are generated from mice that are hyperimmunized with inactivated
SARS
-CoV virions. The hybridomas produce monoclonal antibodies that recognize viral component molecules, including the spike protein (S) and the nucleocapsid protein (N), enabling the immunological detection of
SARS
-CoV by immunofluorescence staining, immunoblot, or an antigen-capture ELISA system. In addition, several S protein-specific antibodies are shown to have in vitro neutralization activity. Thus the monoclonal antibody approach provides useful tools for rapid and specific diagnosis of
SARS
, as well as for possible antibody-based treatment of the disease.
Methods
Mol
Biol 2008
PMID:Establishment and characterization of monoclonal antibodies against SARS coronavirus. 1905 76
In general, a whole virion serves as a simple vaccine antigen and often essential material for the analysis of immune responses against virus infection. However, to work with highly contagious pathogens, it is necessary to take precautions against laboratory-acquired infection. We have learned many lessons from the recent outbreak of
severe acute respiratory syndrome
(
SARS
). In order to develop an effective vaccine and diagnostic tools, we prepared UV-inactivated
SARS
coronavirus on a large scale under the strict Biosafety Level 3 (BSL3) regulation. Our protocol for large-scale preparation of UV-inactivated
SARS
-CoV including virus expansion, titration, inactivation, and ultracentrifugation is applicable to any newly emerging virus we might encounter in the future.
Methods
Mol
Biol 2008
PMID:Large-scale preparation of UV-inactivated SARS coronavirus virions for vaccine antigen. 1905 80
The recent discoveries of novel human coronaviruses, including the coronavirus causing
SARS
, and the previously unrecognized human coronaviruses HCoV-NL63 and HCoV-HKU1, indicate that the family Coronaviridae harbors more members than was previously assumed. All human coronaviruses characterized at present are associated with respiratory illnesses, ranging from mild common colds to more severe lower respiratory tract infections. Since the etiology of a relatively large percentage of respiratory tract diseases remains unidentified, it is possible that for a certain number of these illnesses, a yet unknown viral causative agent may be found. Screening for the presence of novel coronaviruses requires the use of a method that can detect all coronaviruses known at present. In this chapter, we describe a pancoronavirus degenerate primer-based method that allows the detection of all known and possibly unknown coronaviruses by RT-PCR amplification and sequencing of a 251-bp fragment of the coronavirus polymerase gene.
Methods
Mol
Biol 2008
PMID:A pancoronavirus RT-PCR assay for detection of all known coronaviruses. 1905 82
Among the multiple organ disorders caused by the
severe acute respiratory syndrome
coronavirus (SARS-CoV), acute lung failure following atypical pneumonia is the most serious and often fatal event. We hypothesized that two of the hydrophilic structural coronoviral proteins (S and E) would regulate alveolar fluid clearance by decreasing the cell surface expression and activity of amiloride-sensitive epithelial sodium (Na(+)) channels (ENaC), the rate-limiting protein in transepithelial Na(+) vectorial transport across distal lung epithelial cells. Coexpression of either S or E protein with human alpha-, beta-, and gamma-ENaC in Xenopus oocytes led to significant decreases of both amiloride-sensitive Na(+) currents and gamma-ENaC protein levels at their plasma membranes. S and E proteins decreased the rate of ENaC exocytosis and either had no effect (S) or decreased (E) rates of endocytosis. No direct interactions among
SARS
-CoV E protein with either alpha- or gamma-ENaC were indentified. Instead, the downregulation of ENaC activity by
SARS
proteins was partially or completely restored by administration of inhibitors of PKCalpha/beta1 and PKCzeta. Consistent with the whole cell data, expression of S and E proteins decreased ENaC single-channel activity in oocytes, and these effects were partially abrogated by PKCalpha/beta1 inhibitors. Finally, transfection of human airway epithelial (H441) cells with
SARS
E protein decreased whole cell amiloride-sensitive currents. These findings indicate that lung edema in
SARS
infection may be due at least in part to activation of PKC by
SARS
proteins, leading to decreasing levels and activity of ENaC at the apical surfaces of lung epithelial cells.
Am J Physiol Lung Cell
Mol
Physiol 2009 Mar
PMID:SARS-CoV proteins decrease levels and activity of human ENaC via activation of distinct PKC isoforms. 1911
Interest in the potential of monoclonal antibodies (mAbs) to serve as therapeutic agents has surged in the past decade with a major emphasis on human viral diseases. There has been much attention in this area directed towards the human immunodeficiency virus type-1 (HIV-1) and promising research developments have emerged on the inhibition of HIV-1 infection by mAbs and the identification of several highly conserved neutralizing epitopes. More recently, potent fully-human neutralizing mAbs have been developed against a variety of important human viral disease agents including the paramyxoviruses Hendra virus and Nipah virus, and human or humanized mAbs have been developed against
severe acute respiratory syndrome
coronavirus (
SARS
CoV), and West Nile virus, among others. Most of these more recently developed antiviral mAbs have come from the use of antibody phage-display technologies and the implementation of simplified, inexpensive yet efficient methods, for expressing and purifying the initially selected fragment antibodies is of prime importance in further facilitating this area of research.
Methods
Mol
Biol 2009
PMID:Antibody fragment expression and purification. 1925 44
The spike (S) protein of the
severe acute respiratory syndrome
coronavirus (SARS-CoV) is responsible for host cell attachment and fusion of the viral and host cell membranes. Within S the receptor binding domain (RBD) mediates the interaction with angiotensin-converting enzyme 2 (ACE2), the
SARS
-CoV host cell receptor. Both S and the RBD are highly immunogenic and both have been found to elicit neutralizing antibodies. Reported here is the X-ray crystal structure of the RBD in complex with the Fab of a neutralizing mouse monoclonal antibody, F26G19, elicited by immunization with chemically inactivated
SARS
-CoV. The RBD-F26G19 Fab complex represents the first example of the structural characterization of an antibody elicited by an immune response to
SARS
-CoV or any fragment of it. The structure reveals that the RBD surface recognized by F26G19 overlaps significantly with the surface recognized by ACE2 and, as such, suggests that F26G19 likely neutralizes
SARS
-CoV by blocking the virus-host cell interaction.
J
Mol
Biol 2009 May 15
PMID:Structural insights into immune recognition of the severe acute respiratory syndrome coronavirus S protein receptor binding domain. 1932 51
<< Previous
1
2
3
4
5
6
7
8
9
10
Next >>